Fennec Pharmaceuticals Inc has seen a slight dip in its stock price this week, despite recent positive financial announcements.
This week, Fennec Pharmaceuticals Inc (FRX.TO) closed at C$17.10, marking a 1.10% decrease over the past week. The stock has also seen a notable increase of 64.27% year-to-date, indicating strong investor interest amidst recent developments.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$599.65M
52W high
$17.64
52W low
$7.59
1W change
-1.10%
Beta
1.10
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 447.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+447.2% Upside
Current Price
C$17.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
67.7%
Annualized
90-Day Vol
76.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$20.44
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$18.15 | C$14.37 โ C$22.92 |
| 60 trading days | C$19.26 | C$13.85 โ C$26.80 |
| 90 trading days | C$20.44 | C$13.64 โ C$30.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Fennec Pharmaceuticals reported significant growth in product sales for 2025, which may influence investor sentiment positively, even as the stock experiences short-term fluctuations.
Fennec Pharmaceuticals Reports Record Revenue Growth for 2025
The company achieved net product sales of $44.6 million for the year, reflecting a significant milestone in its operational performance.
Bull case
Fennec Pharmaceuticals announced record annual revenue for 2025, with net product sales reaching $44.6 million, a 50% increase from the previous year. This growth, along with positive results from clinical trials, suggests a promising future for the company.
Bear case
Despite the positive financial outlook, the stock has shown volatility. Currently, it has a profit margin of -5.5% and a return on equity (ROE) of -18.6%. Investors should be cautious of these underlying financial metrics.
Recent Price Action
Advertisement
Fennec Pharmaceuticals Inc (FRX.TO) saw its stock close at C$17.10, remaining unchanged on the last trading day. Over the past week, the stock has declined by 1.10%, and over the last month, it has dipped by 3.01%. However, it has shown a remarkable increase of 64.27% year-to-date, reflecting strong investor confidence and interest.
Company News and Developments
While there were no major announcements from Fennec Pharmaceuticals this week, recent headlines indicate a robust financial performance for 2025. The company reported record annual revenues of $44.6 million, driven largely by a 50% year-over-year increase in net product sales. This positive trend may impact future investor sentiment positively, as the company continues to make strides in its clinical trials and product offerings.
Technical Picture
The technical indicators for Fennec Pharmaceuticals show a last close of C$17.10, with a 50-day moving average (MA) at C$15.54, indicating a 10% premium over the current price. The 200-day MA stands at C$12.01, suggesting a 42.4% increase compared to the current price. The stock has traded within a 52-week range of C$7.59 to C$17.64, utilizing 95% of this range. The beta of 1.10 indicates that the stock is slightly more volatile than the broader market. Volume for the last trading day was 234 shares, which is significantly lower than the 20-day average volume of 1,587 shares, reflecting reduced trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
